Inventiva secures €130m debt facility to fund lanifibranor Phase 3
Inventiva has closed a debt financing package totalling up to €130 million to support the late-stage development of lanifibranor, its oral pan-PPAR agonist for metabolic dysfunction-associated steatohepatitis (MASH). The deal, announced on 16 June 2026, brings together Claret Capital Partners, contributing €43 million, and funds and accounts managed by BlackRock. An additional uncommitted tranche of up to €20 million sits alongside the committed structure.
The financing forms part of a wider capital optimisation strategy Inventiva outlined on 2 June 2026, combining debt and equity components. The company is listed on both Euronext Paris and the Nasdaq Global Market under the ticker IVA, and is headquartered in Dijon, France.
The asset and the trial
Lanifibranor is a once-daily oral agent designed to activate all three PPAR receptor subtypes simultaneously, targeting metabolic, inflammatory and fibrotic pathways in a single mechanism. The drug is currently being evaluated in the NATiV3 pivotal Phase 3 trial, with top-line data anticipated in the fourth quarter of 2026. Positive Phase 2b results underpinned investor confidence in the programme, though the company has not yet released full Phase 3 interim data.
Andrew Obenshain, chief executive of Inventiva, said the Phase 2b dataset gave the company "deep conviction in lanifibranor's potential as a differentiated oral therapy for patients living with MASH if approved," and described the financing as implementing a "proactive strategy designed to ensure Inventiva enters this critical clinical moment from a position of strength."
MASH is a progressive condition in which hepatic fat accumulation drives chronic inflammation and fibrosis. Untreated, it can advance to cirrhosis or liver failure. The disease is estimated to affect 20 to 25 per cent of patients already diagnosed with fatty liver disease globally and is projected to become the leading cause of liver transplants in women in the United States, citing a 2018 study in the American Journal of Gastroenterology.
Market context and competitive landscape
The MASH treatment landscape has attracted intense commercial interest since Madrigal Pharmaceuticals received FDA approval for resmetirom (Rezdiffra) in March 2024, the first approved therapy in the indication. Lanifibranor's pan-PPAR mechanism differentiates it from resmetirom's thyroid hormone receptor beta-selective approach, but Inventiva will need to demonstrate a compelling efficacy and safety profile to compete in a market where prescriber familiarity with the first approved agent is growing.
Several other late-stage programmes are in development, including candidates from Novo Nordisk and AstraZeneca, reflecting the scale of unmet need and the commercial opportunity in a condition estimated to affect tens of millions of people worldwide. Oral administration is broadly seen as a practical advantage in a chronic disease setting, though MASH trials have historically seen high placebo response rates that complicate endpoint achievement.
Claret Capital's involvement is notable as an example of growth debt deployed into a listed European biotech at a late clinical stage. The firm cited recent comparable investments in Cinclus Pharma and Abivax as evidence of its expanding life sciences lending strategy. Growth debt of this kind allows companies to extend cash runway without the dilutive pressure of a pure equity raise, which is particularly relevant for Inventiva given the proximity of the Phase 3 readout.
The Q4 2026 top-line readout from NATiV3 will be the defining near-term event for the company. A positive result would be expected to trigger regulatory filing discussions with both the FDA and EMA, while a miss would put significant pressure on the debt structure and the broader capital plan.